Runben Biotechnology Past Earnings Performance
Past criteria checks 5/6
Runben Biotechnology has been growing earnings at an average annual rate of 29.1%, while the Personal Products industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 33% per year. Runben Biotechnology's return on equity is 12.3%, and it has net margins of 22.9%.
Key information
29.1%
Earnings growth rate
4.6%
EPS growth rate
| Personal Products Industry Growth | 7.8% |
| Revenue growth rate | 33.0% |
| Return on equity | 12.3% |
| Net Margin | 22.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Runben Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,048 | 240 | 308 | 27 |
| 31 Dec 23 | 1,033 | 226 | 302 | 26 |
| 30 Sep 23 | 998 | 209 | 291 | 24 |
| 31 Mar 23 | 788 | 142 | 241 | 21 |
| 31 Dec 22 | 856 | 160 | 257 | 20 |
| 31 Dec 21 | 582 | 121 | 155 | 14 |
| 31 Dec 20 | 443 | 95 | 110 | 11 |
| 31 Dec 19 | 279 | 36 | 91 | 8 |
Quality Earnings: 603193 has high quality earnings.
Growing Profit Margin: 603193's current net profit margins (22.9%) are higher than last year (18%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603193's earnings have grown significantly by 29.1% per year over the past 5 years.
Accelerating Growth: 603193's earnings growth over the past year (69.4%) exceeds its 5-year average (29.1% per year).
Earnings vs Industry: 603193 earnings growth over the past year (69.4%) exceeded the Personal Products industry -0.2%.
Return on Equity
High ROE: 603193's Return on Equity (12.3%) is considered low.